Icosavax Shifts Focus On Bivalent Plan For COVID Vax After Antigen Instability Issues

 

• Icosavax Inc 
  ICVX-9.33%+ Free Alerts
   announced the results of an end-to-end drug product investigation of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD). 
• The investigation followed the company's Phase 1/2 topline interim data results. 
• The immunologic response observed for IVX-411 was inconsistent with expectations based on known data for the company's platform and VLP technology.
• The investigation involved a review of in vitro antigen stability and characterization and in vivo potency, as well as a review of data and protocols relating to the transport, storage, and administration.
• Also Read: Icosavax Shares Plummet Following Interim Results From Initial-Stage RSV Vaccine Study.
• Results of the investigation confirmed the company's initial hypothesis that the reduced potency observed for IVX-411 was antigen-specific.
• No similar pattern of instability has been seen in data to date in other Icosavax vaccine candidates, including for RSV and hMPV.
• The company now focuses on a bivalent strategy for COVID-19 candidate development displaying computationally engineered RBD antigens. Candidate selection is expected in 2023.

https://www.benzinga.com/general/biotech/22/07/28262660/icosavax-shifts-focus-on-bivalent-strategy-for-covid-19-vaccine-candidate-after-antigen-instabili